The United Laboratories International Holdings Limited (HKG:3933)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
16.66
-0.81 (-4.64%)
Sep 4, 2025, 4:08 PM HKT
-4.64%
Market Cap32.87B
Revenue (ttm)15.45B
Net Income (ttm)3.36B
Shares Out1.97B
EPS (ttm)1.85
PE Ratio9.02
Forward PE10.35
Dividend0.61 (3.50%)
Ex-Dividend DateSep 25, 2025
Volume15,552,000
Average Volume21,758,413
Open17.47
Previous Close17.47
Day's Range16.55 - 17.48
52-Week Range8.20 - 17.98
Beta0.12
RSI55.59
Earnings DateAug 29, 2025

About HKG:3933

The United Laboratories International Holdings Limited, an investment holding company, engages in the research and development, manufacture, distribution, and sale of pharmaceutical products. It operates through three segments: Bulk Medicine, Intermediate Products, and Finished Products. The company offers oral antibiotics, antimicrobials for injection, anti-cold products, cough medicines, ophthalmic drugs, antiviral drugs, anti-hepatitis B drugs, diabetes drugs, skin drugs for external use, cardiovascular and cerebrovascular drugs, amoxicillin... [Read more]

Sector Healthcare
Founded 1990
Employees 17,000
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 3933
Full Company Profile

Financial Performance

In 2024, HKG:3933's revenue was 13.76 billion, an increase of 0.14% compared to the previous year's 13.74 billion. Earnings were 2.66 billion, a decrease of -1.54%.

Financial numbers in CNY Financial Statements

News

Novo Nordisk Strikes $2B Deal for Obesity Drug

Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by China-based The United Laboratories International Holdings Limited.

5 months ago - Investopedia